Research programme: antibody-drug conjugates - Serina Therapeutics
Alternative Names: POZ-ADCsLatest Information Update: 09 May 2023
At a glance
- Originator Serina Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Polymers
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer